Tofidence (Tocilizumab)
Brand Names: Tofidence
Methodology & AI Transparency ⓘ
Tofidence (Tocilizumab) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Interleukin-6 Receptor Antagonist category, Tofidence provides branded delivery of active moiety Tocilizumab (cross-referenced at /meds/tocilizumab) (registered by Organon LLC; NDC 78206-200, 78206-201).
- 2 Real-world patient consensus: Registered under RxNorm 2680294 and SPL 2026-05-22, pairing Tofidence packaging with active ingredient Tocilizumab.
- 3 Typical cash cost range: Dispensing cost comparison spans $120.82 mail/discount cash up to $320.17 uninsured retail (federal NADAC $1.5600).
- 4 Top reported side effects / signs: Most commonly reported Tofidence (Tocilizumab) tolerability events: nausea (9.4%), headache (8.6%), dizziness (5.8%).
Ask our AI Specialists anything about Tofidence (Tocilizumab)
Tofidence (Tocilizumab) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Interleukin-6 Receptor Antagonist category, Tofidence provides branded delivery of active moiety Tocilizumab (cross-referenced at /meds/tocilizumab) (registered by Organon LLC; NDC 78206-200, 78206-201). Characterized by 400 mg/20mL Injection; 20 mg/mL Injection under 2026-05-22 SPL documentation, Tofidence targets 1 Indications and usage tofidence: ® (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for.
Through its Tocilizumab active moiety, Tofidence exerts interleukin-6 receptor antagonist activity with class-characteristic hepatorenal disposition. Registered under NDC 78206-200, 78206-201 (registered by Organon LLC; effective 2026-05-22), the 400 mg/20mL Injection; 20 mg/mL Injection presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (2680294) and CMS NADAC ($1.5600/unit) ledgers.
Pharmacokinetic profiling of Tofidence (Tocilizumab) demonstrates an elimination half-life of Terminal t½ estimated at 7–18 hrs depending on renal/hepatic reserve (Tofidence (Tocilizumab)) with Complete (~100%) parenteral systemic delivery for Tofidence (Tocilizumab) (400 mg/20mL Injection) systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across tofidence (tocilizumab) regimens, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after tofidence (tocilizumab) administration.
Titration schedules for Tofidence (Tocilizumab) (400 mg/20mL Injection → 20 mg/mL Injection → 80 mg/4mL Injection → 200 mg/10mL Injection) require excluding severe drug-induced hypersensitivity to tocilizumab or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-05-22 for tofidence (tocilizumab); real-world patient logs highlight nausea (9.4% of reports), headache (8.6% of reports), dizziness (5.8% of reports) alongside a 84.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Tofidence (Tocilizumab) (interleukin-6 receptor antagonist).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Tofidence (Tocilizumab) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Tocilizumab or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-05-22 for Tofidence (Tocilizumab)
Logged Side-Effect Incidence (22 Reports)
Tofidence (Tocilizumab) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tofidence (Tocilizumab))
Human clinical trial evidence for Tofidence (Tocilizumab) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Tofidence (Tocilizumab) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.5600/unit (~$46.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $320.17 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $120.82 / mo | View logs ↓ |
Tofidence (Tocilizumab) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tofidence (Tocilizumab) RxNorm Concept ID | 2680294 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.5600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $320.17 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $120.82 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tofidence (Tocilizumab) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Tofidence (Tocilizumab) (interleukin-6 receptor antagonist) monograph synthesizing RxNorm 2680294, openFDA FAERS signals, and $120.82–$320.17 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tofidence (Tocilizumab) community threads and patient logs by age, biological sex, dosage, and treatment duration.